Children’s Minnesota Pharmacogenomics
Transcript of Children’s Minnesota Pharmacogenomics
![Page 1: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/1.jpg)
Children’s Minnesota Pharmacogenomics
Implementation
David Gregornik, BA, BS, Pharm.D. BCOP
Pharmacogenomics Program Director
![Page 2: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/2.jpg)
2 | © 2016
One of the largest freestanding pediatric health systems in the
United States
Children’s Minnesota
Minneapolis St Paul
429 Staffed beds
5,230 Employees
![Page 3: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/3.jpg)
3 | © 2016
• 12 Primary care clinics
• 2 Emergency Departments
• 9 Specialty care sites
• 6 Rehabilitation sites
Children’s Minnesota
![Page 4: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/4.jpg)
4 | © 2016
![Page 5: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/5.jpg)
5 | © 2016
• Membership
− Pharmacist, Chair
− Genetics/genomics
− Hematology/oncology
− Behavioral health
− Anesthesiology
− Pathology
− Clinical informatics
− CMIO
− Administration/strategy
− Ad hoc – Antimicrobial Stewardship, Pain and Palliative Care, Developmental Pediatrics
Pharmacogenomics Oversight Committee (POC)
![Page 6: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/6.jpg)
6 | © 2016
• Clinic opened 2/10/2017
• Pharmacist and genetic counselor
• Referred by primary care, behavioral health, and
developmental pediatrics services
• Appointment types:
− Pre-test evaluation appointment
Prior authorization obtained before PGx testing ordered
− Results review appointment
• 2 – 3 patients 1 day per week
• 1 – 2 inpatient consults per month
Pharmacogenomics Clinic
![Page 7: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/7.jpg)
7 | © 2016
Children’s Minnesota EHR Implementation
• PGx result entry
• PGx result display
• Electronic clinical decision support
![Page 8: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/8.jpg)
8 | © 2016
PGx Result Entry in EHR – Cerner PowerForm
• Results received in PDF format from all PGx labs
−Requires result entry by hand
• PowerForm Functionality
−Entry of discrete PGx results
−Automatically builds interpretive consults
−Allows for customized interpretive consults
• Standard consult text exists in a table outside of the results
page.
−Allows for updating interpretive consult without updating each
result individually.
![Page 9: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/9.jpg)
9 | © 2016
PGx Result Entry in EHR – Cerner PowerForm
![Page 10: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/10.jpg)
10 | © 2016
PGx Result Entry in EHR – Cerner PowerForm
![Page 11: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/11.jpg)
11 | © 2016
PGx Result Entry in EHR – Cerner PowerForm
![Page 12: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/12.jpg)
12 | © 2016
Pharmacogenomic Results Page (Cerner M-page)
![Page 13: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/13.jpg)
13 | © 2016
Pharmacogenomic Results Page (Cerner M-page)
Gene/Drug Interactions
highlighted in RED
![Page 14: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/14.jpg)
14 | © 2016
Interpretive Consult for Individual Results
Standard Consult Format:
•Diplotype
•Phenotype
•Dosing Recommendation
![Page 15: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/15.jpg)
15 | © 2016
Individualized Medication Recommendations
Additional Resources
& Contact Information
Medications with evidence
based gene/drug interactions
![Page 16: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/16.jpg)
16 | © 2016
Point of Care Alerts for High Risk Gene/Drug
Interactions
![Page 17: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/17.jpg)
17 | © 2016
Point of Care Alert – 2 Gene Results
![Page 18: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/18.jpg)
18 | © 2016
• Implementations to date
− TPMT: Thioguanine, 6-mercaptopurine & Azathioprine
− CYP2C19: Voriconazole, Citalopram, Escitalopram
− CYP2D6: Ondansetron, Tramadol, Aripiprazole, Nortriptyline,
Desipramine
− CYP2C19 & CYP2D6: Amitriptyline, Imipramine, Doxepin
Pharmacogenomics at Children’s Minnesota
![Page 19: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/19.jpg)
19 | © 2016
Children’s Minnesota Data
• Genes implemented in
EHR:
−TPMT
−CYP2C19
−CYP2D6
As of December 31, 2017
• N = 394 patients
• 839 discrete results
46%
54%
Patients with Actionable Results
Normal Results
Actionable Results
![Page 20: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/20.jpg)
20 | © 2016
• Strong administration commitment
• Multidisciplinary oversight committee
• Dedicated pharmacist leading implementation
• Enthusiastic pharmacy service
• Customizable (Cerner) EHR
• Experienced IT analyst
• PGx laboratory with > 10 years of experience
• CPIC Guidelines
Success Factors
![Page 21: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/21.jpg)
21 | © 2016
• Reimbursement for testing and professional services
• Educating professional staff
• Educating patients
• EHR interoperability – Cerner vs. eClinical Works
Ongoing Challenges
![Page 22: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/22.jpg)
22 | © 2016
Thank You!
Pharmacogenomics Oversight Committee
• Bruce Bostrom
• David Dassenko
• Paul Jensen
• Jen Miller
• Kim Oberstar
• Robyn Reed
• Ann Samuelson
• Gunter Scharer
• Susan Sencer
• Rabindra Tambyraja
• Mike Troy
• Colleen Wherley
• Cathy Wright
Expert Resources
• Stefan Friedrichsdorf
• Steve Grapentine
• Bill Pomputius
• Ulrich Broeckel
• Mark Dunnenberger
• Cyrine Haidar
• James Hoffman
Administration/Strategy/Informatics
• Laura Madsen
• Mary Ellen Mattson
• Nancy Mendelsohn
• Trevor Sawallish
• Judy Wenzel
• Carol Wilcox
• Greg Zarambo
![Page 23: Children’s Minnesota Pharmacogenomics](https://reader036.fdocuments.us/reader036/viewer/2022062318/62a90dcb368b0202d46ee2b4/html5/thumbnails/23.jpg)
23 | © 2016
Questions?